Paper accepted on the clinical effects of HIF-PHI vadadustat in hemodialysis patients
” Effects of Vadadustat on Hemoglobin Concentrations in Patients Receiving Hemodialysis Previously Treated with Erythropoiesis Stimulating Agents ”
Congratulations to the authors: Volker H. Haase, Glenn M. Chertow, Geoffrey A. Block, Pablo E. Pergola, Emil deGoma, Zeeshan Khawaja, Amit Sharma, Bradley J. Maroni and Peter A. McCullough.
Erythropoiesis-stimulating agents (ESAs) can correct anemia in chronic kidney disease (CKD) but are associated with increased risks of cardiovascular events. Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain (HIF-PHD) dioxygenases, is an oral investigational agent in development for the treatment of anemia in patients with CKD. read more…
click here for a link to erythropoiesis, iron metabolism and renal anemia
click here for teaching on renal anemia